Platelet-rich plasma and extracellular vesicle preparations both deliver biologically derived signalling molecules with relevance to skin health. Both work through pathways involved in tissue repair, growth factor signalling, and inflammation modulation. Beyond that shared layer, they are distinct categories with different practical properties. Choosing between them is a clinical decision shaped by the use case, the patient, the available evidence base, and the operational constraints of the practice.
What PRP is, and where it sits today
PRP is prepared from the patient's own blood, typically through a single-step or two-step centrifugation that concentrates platelets and the growth factors stored in their alpha granules, including PDGF, TGF-β, VEGF, EGF, and IGF-1. The clinical literature for PRP is mature in several specific domains. Wound healing, hair restoration, and certain aesthetic medicine applications have a body of randomized and observational evidence behind them. PRP remains the current clinical benchmark for biologically based skin regeneration procedures performed in the office setting.
The technique has practical limitations that are clinically meaningful and well documented. Composition varies significantly between patients. Younger patients typically produce PRP with higher growth factor content and better in vitro performance than older patients drawn from the same protocol. The final preparation also varies depending on the technician performing the venipuncture and centrifugation, which adds operator-induced variability on top of the donor-induced variability. There is no universally standardized concentration protocol across providers, which makes cross-clinic outcome comparisons difficult.
The procedure itself requires a venipuncture. That introduces a real patient-side cost: invasiveness, transient or persistent discomfort, the inherent risks of any blood draw (bruising, hematoma, vasovagal responses, rare infection), and biological activity that degrades rapidly after collection. None of these are deal-breakers for the clinical settings PRP is built for. They are constraints that shape where PRP fits.
What characterized EV preparations offer
A characterized EV preparation is a different modality, even though the active material is also a population of biological signalling particles. The key differences sit in three places.
Reproducibility. A characterized EV preparation is manufactured to a specification, not drawn from each patient on the day of treatment. NTA-verified particle counts, proteomics-confirmed payload, batch-specific Certificate of Analysis. The active material is the same across patients within the same lot. There is no donor-level variability and no operator-level variability in the active itself.
Delivery. Topical application is non-invasive. No venipuncture, no centrifugation, no procedural pain. The patient experience is closer to a serum application than to a clinical procedure. For practices that want to extend EV-class signalling beyond the in-office setting, this is an enabling difference.
Storage and shelf life. Properly formulated EV preparations carry a shelf life under appropriate cold-chain handling that is meaningfully longer than the post-collection viability of PRP. The active does not have to be produced and used in the same hour.
The current limitation, stated honestly, is that the clinical evidence base for cosmetic EV preparations, including plant-derived formulations, is earlier in development than PRP's. The mechanistic plausibility, the preclinical signal, the manufacturing standards: those are well established. Confirmed clinical outcome data at large scale across populations is the next chapter of the work, and it is the one credible EV manufacturers are currently writing.
How they actually relate
These are distinct rather than competing categories. PRP remains the evidence-backed choice for clinically administered regenerative procedures targeting structural outcomes, especially in wound healing, hair restoration, and tissue repair. EVs are positioned as a standardized, scalable, non-invasive approach delivering characterized biological signals, suited to topical cosmetic applications where reproducibility, safety profile, and patient accessibility are the dominant constraints.
Many practices will end up using both, because they are not solving the same problem. PRP is well suited to in-office regenerative procedures with structural endpoints. A characterized EV serum is well suited to topical cosmetic protocols, post-procedure recovery, and at-home maintenance regimens that the practice prescribes alongside in-office work.
What "characterized" actually means
The comparison only holds if the EV preparation in question is genuinely characterized. An "exosome serum" with no disclosed particle count, no Certificate of Analysis, and no documented isolation method is not the same product class as a preparation with NTA-verified concentration, proteomics-confirmed cargo, and batch-specific CoAs. The rigour bar here matters.
BioThera's mPDEV Serum is designed for the characterized end of this spectrum: a topically delivered, proteomics-verified, NTA-confirmed preparation with an active dermatologist-led clinical evaluation program. The point of the EV-versus-PRP comparison is not to argue one against the other. It is to make the operational properties of each visible enough that a clinician can decide where each one fits in the practice.